# US 2012/0251487 A1 · Compounds and pharmaceutical compositions for the treatment of viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251487 A1
- Document ID: US20120251487A1
- Status: Published application
- Kind: A1
- Application number: 13/436,587
- Filed: 2012-03-30
- Published: 2012-10-04
- Earliest claimed: 2011-03-31
- Assignees: Idenix Pharmaceuticals, Inc.
- Inventors: Dominique SURLERAUX
- Web page: https://patentgrep.com/patent/US20120251487A1

## CPC

- C07H 21/02: with ribosyl as saccharide radical
- A61K 31/7042: Compounds having saccharide radicals and heterocyclic rings
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 31/708: having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07H 19/167: with ribosyl as the saccharide radical
- C07H 19/20: with the saccharide radical esterified by phosphoric or polyphosphoric acids
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

## Claims

### Claim 1

A compound of Formula I:
or a pharmaceutically acceptable salt, solvate, a stereoisomeric, tautomeric or polymorphic form thereof, wherein
A is
R is a moiety derivable by removal of a hydrogen from a hydroxy group of an antiviral drug, such as a nucleoside or nucleoside analog;
X is O or S;
Q is OR4, SR4 or NR5R6;
each E is independently CR7R8;
n is 1 or 2;
Ry is alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, amino, aminoalkyl, hydroxyalkyl, heterocyclyl or heteroaryl, all optionally substituted;
R1 and R2 are selected as follows:
i) R1 and R2 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl;
ii) R1 and R2 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring, wherein the ring is unsubstituted or substituted by C(O)Q1; or
iii) R1 is hydrogen, alkyl or cycloalkyl, and R2 is (G)mC(O)Q1, wherein
Q1 is OR4, SR4 or NR5R6;
each G is independently CR7R8; and
each m is 1 or 2;
R3 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or when n is 1, R3 and R7 together with the nitrogen and carbon atoms to which they are attached form a 4-7 membered heterocyclic ring, wherein the ring is unsubstituted or substituted by C(O)Q1;
R4 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
R5 and R6 are selected as follows:
i) R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or
ii) R5 and R6 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring; and
R7 and R8 are selected as follows:
i) R7 and R8 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy; or
ii) R7 and R8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring; and
wherein if R2 is (G)mC(O)Q1, G is CR7R8; m is 1, and one of R7 or R8 is hydrogen, the other of R7 and R8 is not methyl.

### Claim 2 (depends on 1)

The compound of claim 1 of Formula I, wherein R7 and R8 are selected as follows:
i) R7 and R8 are each independently hydrogen, C2-C10 alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy; or
ii) R7 and R8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring;

### Claim 3 (depends on 1)

The compound of claim 1, wherein one of R7 or R8 is C2-C6 alkyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein
R1 and R3 are each hydrogen;
R2 is (G)mC(O)Q1; and
m is 1.

### Claim 5 (depends on 1)

The compound of claim 1, wherein
R1 and R3 are each hydrogen;
R2 is (G)mC(O)Q1; and
m is 2.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Q and Q1 are each OR4 and each R4 is alkyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein
R1 and R3 are each hydrogen;
R2 is (G)mC(O)Q1;
m is 1;
Q1 is OR4; and
R4 is alkyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein
R1 and R3 are each hydrogen;
R2 is (G)mC(O)Q1;
m is 1;
Q1 is OR4; and
R4 is alkyl.
each R7 is hydrogen; and
each R9 is alkyl, alkylaryl or alkylheteroaryl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein
R1 and R2 together with the nitrogen atom on which they are substituted form a 5 membered heterocyclic ring substituted by C(O)Q1;
n is 1;
R3 and R7 together with the nitrogen and carbon atoms to which they are attached form a 5 membered heterocyclic ring substituted by C(O)Q1;
each Q1 is OR4;
each R4 is alkyl;
each R7 is hydrogen; and
each R9 is alkyl, alkylaryl or alkylheteroaryl.

### Claim 10 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 11

A compound of Formula II:
or a pharmaceutically acceptable salt, a stereoisomeric, tautomeric or polymorphic form thereof, wherein;
Base is a substituted or unsubstituted purine or pyrimidine;
W is alkyl, cycloalkyl, alkenyl, cycloalkenyl or alkynyl;
X is O or S;
Y is hydrogen or OR9;
Z is hydrogen, OR10, SR10, NR5R6, F, Cl, Br or I;
Q is OR4, SR4 or NR5R6;
each E is independently CR7R8;
each n is 1 or 2;
R1 and R2 are selected as follows:
i) R1 and R2 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl;
ii) R1 and R2 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring, wherein the ring is unsubstituted or substituted by C(O)Q1; or
iii) R1 is hydrogen, alkyl or cycloalkyl, and R2 is (G)mC(O)Q1, wherein
Q1 is OR4, SR4 or NR5R6;
each G is independently CR7R8; and
each m is 1 or 2;
R3 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or
when n is 1, R3 and R7 together with the nitrogen and carbon atoms to which they are attached form a 4-7 membered heterocyclic ring, wherein the ring is unsubstituted or substituted by C(O)Q1;
R4 is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl;
R5 and R6 are selected as follows:
i) R5 and R6 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or
ii) R5 and R6 together with the nitrogen atom on which they are substituted form a 3-7 membered heterocyclic or heteroaryl ring;
R7 and R8 are selected as follows:
i) R7 and R8 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, alkylheterocyclyl or alkylheteroaryl, wherein alkyl is optionally substituted by alkoxy; or
ii) R7 and R8 together with the carbon atom to which they are attached form a 3-7 membered cycloalkyl ring;
R9 and R10 are selected as follows:
i) R9 and R10 are each independently hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, cycloalkyl or cycloalkenyl; or
ii) R9 and R10 together with C(O) and the oxygen or sufur atoms on which they are substituted form a 5 membered ring.

### Claim 12 (depends on 11)

The compound of claim 11, wherein if R2 is (G)mC(O)Q1, G is CR7R8, m is 1, and one of R7 or R8 is hydrogen; the other of R7 and R8 is not methyl.

### Claim 13 (depends on 11)

The compound of claim 11, wherein Y is OR9 and Z is OR10 or F.

### Claim 14 (depends on 11)

The compound of claim 11, wherein W is alkyl, alkenyl or alkynyl.

### Claim 15 (depends on 14)

The compound of claim 14, wherein W is alkyl.

### Claim 16 (depends on 11)

The compound of claim 11, wherein W is ethynyl; Y is OR9; Z is F; and R9 is hydrogen.

### Claim 17 (depends on 11)

The compound of claim 11, wherein W is methyl; Y is OR9; Z is F; and R9 is hydrogen.

### Claim 18 (depends on 11)

The compound of claim 11, wherein W is methyl; Y is OR9; Z is OR10; and R9 and R10 are each hydrogen.

### Claim 19 (depends on 11)

The compound of claim 11, wherein R1 and R3 are each hydrogen; and R2 is (G)mC(O)Q1.

### Claim 20 (depends on 11)

The compound of claim 11, wherein Q and Q1 are each OR4.

### Claim 21 (depends on 11)

The compound of claim 11, wherein Q and Q1 are each SR4.

### Claim 22 (depends on 11)

The compound of claim 11, wherein each R4 is alkyl.

### Claim 23 (depends on 11)

The compound of claim 11, wherein Q and Q1 are each NR5R6.

### Claim 24 (depends on 11)

The compound of claim 11, wherein X is O.

### Claim 25 (depends on 11)

The compound of claim 11, wherein m is 1.

### Claim 26 (depends on 11)

The compound of claim 11, wherein n is 1.

### Claim 27 (depends on 11)

The compound of claim 11, wherein m is 2.

### Claim 28 (depends on 11)

The compound of claim 11, wherein n is 2.

### Claim 29 (depends on 11)

The compound of claim 11, wherein each R7 is hydrogen; and each R8 is independently alkyl, aryl, aralkyl or alkylheteroaryl.

### Claim 30 (depends on 29)

The compound of claim 29, wherein each R8 is C2-C10 alkyl.

### Claim 31 (depends on 29)

The compound of claim 29, wherein each R8 is C2-C6 alkyl.

### Claim 32 (depends on 29)

The compound of claim 29, wherein each R8 is C3-C6 alkyl.

### Claim 33 (depends on 29)

The compound of claim 29, wherein each R8 is isobutyl.

### Claim 34 (depends on 29)

The compound of claim 29, wherein each R8 is sec-butyl.

### Claim 35 (depends on 29)

The compound of claim 29, wherein each R8 is phenyl.

### Claim 36 (depends on 29)

The compound of claim 29, wherein each R8 is benzyl.

### Claim 37 (depends on 29)

The compound of claim 29, wherein each R8 is 1-H-indol-3-ylmethyl.

### Claim 38 (depends on 11)

The compound of claim 11, wherein each of R7 and R8 is alkyl.

### Claim 39 (depends on 11)

The compound of claim 11, wherein R7 and R8 together with the carbon atom to which they are attached form a 5 membered cycloalkyl ring.

### Claim 40 (depends on 1)

The compound of claim 1, wherein, when E, Q, Q1, R1, R2, R5, R6, n and m form at least one amino acid group, the amino acid is in the L-configuration.

### Claim 41 (depends on 1)

The compound of claim 1, wherein Base is adenine, cytosine, guanine, hypoxanthine, thymine or uridine.

### Claim 42 (depends on 41)

The compound of claim 41, wherein Base is cytosine.

### Claim 43 (depends on 41)

The compound of claim 41, wherein Base is guanine.

### Claim 44 (depends on 41)

The compound of claim 41, wherein Base is uridine.

### Claim 45 (depends on 11)

The compound of claim 11, wherein Base is selected from one of formulae (i) to (xxvi):
wherein each RL is independently hydrogen, alkyl, cycloalkyl, acyl, carbamyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, sulfonate ester, alkyl sulfonyl, aryl sulfonyl, arylalkyl sulfonyl, a lipid, a phospholipid, an amino acid or a carbohydrate; and each RM and RN is independently hydrogen or alkyl; or RL and RM together with the N atom to which they are attached from heterocyclyl.

### Claim 46 (depends on 45)

The compound of claim 45, wherein RL is hydrogen, alkyl or cycloalkyl.

### Claim 47 (depends on 45)

The compound of claim 45, wherein RL is cyclopropyl or cyclopentyl.

### Claim 48 (depends on 45)

The compound of claim 45, wherein RL is methyl, ethyl, propyl, or isopropyl.

### Claim 49 (depends on 45)

The compound of claim 45, wherein RM is hydrogen.

### Claim 50 (depends on 45)

The compound of claim 45, wherein RM is methyl.

### Claim 51 (depends on 45)

The compound of claim 45, wherein Base is selected from
wherein RL and RM together with the N atom to which they are attached from pyrrolidinyl or morpholinyl.

### Claim 52 (depends on 1)

The compound of claim 1, wherein R is a moiety derivable by removal of a hydrogen from a hydroxy group of selected from ribavirin, viramidine, valopicitabine, PSI-6130, PSI-6206, PSI-35938 and R1479.

### Claim 53 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt, a stereoisomeric, tautomeric or polymorphic form thereof, of the formula:
wherein
Ry is alkyl or substituted alkyl;
R1 is hydrogen, alkyl or aralkyl;
R2 is hydrogen or alkyl;
R9 and R10 are each hydrogen;
RL is hydrogen, alkyl or cycloalkyl;
each RM and RN is independently hydrogen or alkyl; or
RL and RM together with the N atom to which they are attached from heterocyclyl.

### Claim 54 (depends on 53)

The compound of claim 53, wherein Ry is —C(CH3)2CH2OH and R1 is benzyl.

### Claim 55 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt, a stereoisomeric, tautomeric or polymorphic form thereof, of the formula:

### Claim 56 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient, carrier or diluent.

### Claim 57 (depends on 56)

The pharmaceutical composition of claim 56, wherein the composition is an oral formulation.

### Claim 58 (depends on 1)

A method for the treatment of a host infected with a hepatitis C virus, comprising the administration of an effective treatment amount of a compound or composition of claim 1.

### Claim 59 (depends on 58)

The method of claim 58, wherein the host is a human.

### Claim 60 (depends on 58)

The method of claim 58, wherein said administration directs a substantial amount of said compound or pharmaceutically acceptable salt or stereoisomer thereof to the liver of said host.

### Claim 61 (depends on 58)

The method of claim 58, wherein said compound or composition is administered in combination or alternation with a second anti-viral agent optionally selected from the group consisting of an interferon, a ribavirin, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, a phenanthrenequinone, a thiazolidine derivative, a thiazolidine, a benzanilide, a helicase inhibitor, a polymerase inhibitor, a nucleotide analogue, a gliotoxin, a cerulenin, an antisense phosphorothioate oligodeoxynucleotide, an inhibitor of IRES-dependent translation, and a ribozyme.

### Claim 62 (depends on 61)

The method of claim 61, wherein the second agent is selected from the group consisting of pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta and interferon γ-1b.
